Top

Published in:

01-01-2019 | Original Article

Development and comparison of two H5N8 influenza A vaccine candidate strains

Authors: Mi-Seon Lee, Eun Young Jang, Junhyung Cho, Kisoon Kim, Chan Hee Lee, Hwajung Yi

Published in: Archives of Virology | Issue 1/2019

Abstract

Avian influenza viruses circulating in birds have caused outbreaks of infection in poultry and humans, thereby threatening public health. Recently, a highly pathogenic avian influenza (HPAI) virus (H5N8) of clade 2.3.4.4 emerged in Korea and other countries and caused multiple outbreaks in domestic and wild birds, with concerns for human infection. To combat HPAI viral infections, novel vaccines are likely to be the most effective approach. Therefore, in this study, we generated H5N8 vaccine candidate viruses based on a Korean isolate (A/broiler duck/Korea/Buan2/2014). The vaccine candidate viruses were 2:6 reassortants expressing the two surface glycoproteins of A/broiler duck/Korea/Buan2/2014 on an A/Puerto Rico/8/34 (PR8) backbone generated by using an eight-plasmid-based reverse genetics system with or without replacement of the multi-basic amino acid cleavage motif (MBCM, a crucial pathogenic factor in HPAI virus) with a bi-basic amino acid cleavage motif (BBCM) in their HA. An H5N8 vaccine candidate virus containing the BBCM showed attenuated pathogenesis in embryonated eggs and exhibited less virulence in the infected mice compared with the wild H5N8 virus containing an MBCM. Vaccination with an inactivated preparation of the vaccine candidate virus protected mice from lethal H5N8 viral challenge. This is the first report of the development and evaluation of H5N8 vaccine strains (with an MBCM or BBCM) of HA clade 2.3.4.4 as vaccine candidates. Our findings suggest that H5N8 strains with a BBCM instead of an MBCM might be considered for H5N8 vaccine seed virus development or as a reference vaccine against H5N8 viral strains.

Claes F, Morzaria SP, Donis RO (2016) Emergence and dissemination of clade 2.3.4.4 H5Nx influenza viruses—how is the Asian HPAI H5 lineage maintained. Curr Opin Virol 16:158–163. https://doi.org/10.1016/j.coviro.2016.02.005 CrossRefPubMed

Shortridge KF, Zhou NN, Guan Y, Gao P, Ito T, Kawaoka Y, Kodihalli S, Krauss S, Markwell D, Murti KG, Norwood M, Senne D, Sims L, Takada A, Webster RG (1998) Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 252(2):331–342. https://doi.org/10.1006/viro.1998.9488 CrossRefPubMed

Poovorawan Y, Pyungporn S, Prachayangprecha S, Makkoch J (2013) Global alert to avian influenza virus infection: from H5N1 to H7N9. Pathog Glob Health 107(5):217–223. https://doi.org/10.1179/2047773213Y.0000000103 CrossRefPubMedPubMedCentral

Swayne D, Suarez D (2000) Highly pathogenic avian influenza. Rev Sci Tech 19(2):463–475CrossRefPubMed

WHO (2017) Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO, 2003-2017. http://www.who.int/influenza/human_animal_interface/2017_07_25_tableH5N1.pdf

Zhao K, Gu M, Zhong L, Duan Z, Zhang Y, Zhu Y, Zhao G, Zhao M, Chen Z, Hu S, Liu W, Liu X, Peng D, Liu X (2013) Characterization of three H5N5 and one H5N8 highly pathogenic avian influenza viruses in China. Vet Microbiol 163(3):351–357. https://doi.org/10.1016/j.vetmic.2012.12.025 CrossRefPubMed

Wu H, Peng X, Xu L, Jin C, Cheng L, Lu X, Xie T, Yao H, Wu N (2014) Novel reassortant influenza A(H5N8) viruses in domestic ducks, Eastern China. Emerg Infect Dis 20(8):1315–1318. https://doi.org/10.3201/eid2008.140339 CrossRefPubMedPubMedCentral

Jhung MA, Nelson DI, Control CfD, Prevention (2015) Outbreaks of avian influenza A (H5N2),(H5N8), and (H5N1) among birds—United States, December 2014–January 2015. MMWR Morb Mortal Wkly Rep 64(4):111PubMedPubMedCentral

Lee D-H, Torchetti MK, Winker K, Ip HS, Song C-S, Swayne DE (2015) Intercontinental spread of Asian-origin H5N8 to North America through Beringia by migratory birds. J Virol 89(12):6521–6524. https://doi.org/10.1128/JVI.00728-15 CrossRefPubMedPubMedCentral

10.

Lee Y-J, Kang H-M, Lee E-K, Song B-M, Jeong J, Kwon Y-K, Kim H-R, Lee K-J, Hong M-S, Jang I, Choi K-S, Kim J-Y, Lee H-J, Kang M-S, Jeong O-M, Baek J-H, Joo Y-S, Park YH, Lee H-S (2014) Novel reassortant influenza A (H5N8) viruses, South Korea. Emerg Infect Dis 20(6):1087–1089. https://doi.org/10.3201/eid2006.140233 CrossRefPubMedPubMedCentral

11.

Si Y-J, Choi WS, Kim Y-I, Lee I-W, Kwon H-I, Park S-J, Kim E-H, Sm Kim, Kwon J-J, Song M-S, Kim C-J, Choi Y-K (2016) Genetic characteristics of highly pathogenic H5N8 avian influenza viruses isolated from migratory wild birds in South Korea during 2014-2015. Arch Virol 161(10):2749–2764. https://doi.org/10.1007/s00705-016-2979-4 CrossRefPubMed

12.

World Organization for Animal Health (OIE) (2017) http://www.oie.int/wahis_2/temp/reports/en_fup_0000025168_20171120_170003.pdf

13.

Woo CKJ-H, Kwon JH, Lee D-H, Kim Y, Lee K, Jo S-D, Son KD, Oem J-K, Wang S-J, Kim Y, Shin J, Song C-S, Jheong W, Jeong J (2017) Novel reassortant. Arch Virol. 162(12):3887. https://doi.org/10.1007/s00705-017-3547-2 CrossRefPubMedPubMedCentral

14.

Shortridge KF (1995) The next pandemic influenza virus? Lancet 346(8984):1210–1212. https://doi.org/10.1016/S0140-6736(95)92906-1 CrossRefPubMed

15.

Webster RG, Peiris M, Chen H, Guan Y (2006) H5N1 outbreaks and enzootic influenza. Biodiversity 7(1):51–55. https://doi.org/10.1080/14888386.2006.9712795 CrossRef

16.

To KKW, Ng KHL, Que T-L, Chan JMC, Tsang K-Y, Tsang AKL, Chen H, Yuen K-Y (2012) Avian influenza A H5N1 virus: a continuous threat to humans. Emerg Microbes Infect 1:e25. https://doi.org/10.1038/emi.2012.24 PubMedPubMedCentralCrossRef

17.

Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A, Bosman A (2004) Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363(9409):587–593. https://doi.org/10.1016/S0140-6736(04)15589-X CrossRefPubMed

18.

Ostrowsky B, Huang A, Terry W, Anton D, Brunagel B, Traynor L, Abid S, Johnson G, Kacica M, Katz J, Edwards L, Lindstrom S, Klimov A (2003) Uyeki TM (2012) Uyeki TM (2012) Low pathogenic avian influenza A (H7N2) virus infection in immunocompromised adult, New York, USA. Emerg Infect Dis 18(7):1128–1131. https://doi.org/10.3201/eid1807.111913 CrossRef

19.

Tweed SA, Skowronski DM, David ST, Larder A, Petric M, Lees W, Li Y, Katz J, Krajden M, Tellier R, Halpert C, Hirst M, Astell C, Lawrence D, Mak A (2004) Human Illness from Avian Influenza H7N3, British Columbia. Emerg Infect Dis 10(12):2196–2199. https://doi.org/10.3201/eid1012.040961 CrossRefPubMedPubMedCentral

20.

Arzey GG, Kirkland PD, Arzey KE, Frost M, Maywood P, Conaty S, Hurt AC, Deng Y-M, Iannello P, Barr I, Dwyer DE, Ratnamohan M, McPhie K, Selleck P (2012) Influenza virus A (H10N7) in chickens and poultry abattoir workers, Australia. Emerg Infect Dis 18(5):814–816. https://doi.org/10.3201/eid1805.111852 CrossRefPubMedPubMedCentral

21.

De Jong J, Claas E, Osterhaus A, Webster R, Lim W (1997) A pandemic warning? Nature 389(6651):554. https://doi.org/10.1038/39218 CrossRefPubMed

22.

Campbell PJ, Danzy S, Kyriakis CS, Deymier MJ, Lowen AC, Steel J (2014) The M segment of the 2009 pandemic influenza virus confers increased neuraminidase activity, filamentous morphology, and efficient contact transmissibility to A/Puerto Rico/8/1934-based reassortant viruses. J Virol 88(7):3802–3814. https://doi.org/10.1128/JVI.03607-13 CrossRefPubMedPubMedCentral

23.

Matsuoka Y, Chen H, Cox N, Subbarao K, Beck J, Swayne D (2003) Safety evaluation in chickens of candidate human vaccines against potential pandemic strains of influenza. Avian Dis 47(s3):926–930. https://doi.org/10.1637/0005-2086-47.s3.926 CrossRefPubMed

24.

Rodriguez A, Pérez-González A, Hossain MJ, Chen L-M, Rolling T, Pérez-Breña P, Donis R, Kochs G, Nieto A (2009) Attenuated strains of influenza A viruses do not induce degradation of RNA polymerase II. J Virol 83(21):11166–11174. https://doi.org/10.1128/JVI.01439-09 CrossRefPubMedPubMedCentral

25.

Senne D, Panigrahy B, Kawaoka Y, Pearson J, Süss J, Lipkind M, Kida H, Webster R (1996) Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis 40(2):425–437. https://doi.org/10.2307/1592241 CrossRefPubMed

26.

Alexander DJ (2007) An overview of the epidemiology of avian influenza. Vaccine 25(30):5637–5644. https://doi.org/10.1016/j.vaccine.2006.10.051 CrossRefPubMed

27.

Hoffmann E, Krauss S, Perez D, Webby R, Webster RG (2002) Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20(25):3165–3170. https://doi.org/10.1016/S0264-410X(02)00268-2 CrossRefPubMed

28.

Hoffmann E, Stech J, Guan Y, Webster R, Perez D (2001) Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 146(12):2275–2289. https://doi.org/10.1007/s007050170002 CrossRefPubMed

29.

Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N, Matsuoka Y (2003) Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305(1):192–200. https://doi.org/10.1006/viro.2002.1742 CrossRefPubMed

30.

Wohlbold TJ, Hirsh A, Krammer F (2015) An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13. Vaccine 33(9):1102–1106. https://doi.org/10.1016/j.vaccine.2015.01.026 CrossRefPubMedPubMedCentral

31.

Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27(3):493–497. https://doi.org/10.1093/oxfordjournals.aje.a118408 CrossRef

32.

Palmer DF, Dowdle WR, Coleman MT, Schild GC (1975) Hemagglutination-inhibition test. In: Advanced laboratory techniques for influenza diagnosis: procedural guide. U.S. Department of Health, Education and Welfare, Atlanta, GA, pp 25–62

33.

Grund S, Adams O, Wählisch S, Schweiger B (2011) Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus. J Virol Methods 171(2):369–373. https://doi.org/10.1016/j.jviromet.2010.11.024 CrossRefPubMed

34.

Kim HM, Kim C-K, Lee N-J, Chu H, Kang C, Kim K, Lee J-Y (2015) Pathogenesis of novel reassortant avian influenza virus A (H5N8) Isolates in the ferret. Virology 481:136–141. https://doi.org/10.1016/j.virol.2015.02.042 CrossRefPubMed

35.

Verhagen JH, Herfst S, Fouchier RA (2015) How a virus travels the world. Science 347(6222):616–617. https://doi.org/10.1126/science.aaa6724 CrossRefPubMed

36.

Arriola CS, Nelson DI, Deliberto TJ, Blanton L, Kniss K, Levine MZ, Trock SC, Finelli L, Jhung MA, the HIG (2015) Infection risk for persons exposed to highly pathogenic avian influenza A H5 virus-infected birds, United States, December 2014–March 2015. Emerg Infect Dis 21(12):2135–2140. https://doi.org/10.3201/eid2112.150904 CrossRefPubMedPubMedCentral

37.

Pan M, Gao R, Lv Q, Huang S, Zhou Z, Yang L, Li X, Zhao X, Zou X, Tong W, Mao S, Zou S, Bo H, Zhu X, Liu L, Yuan H, Zhang M, Wang D, Li Z, Zhao W, Ma M, Li Y, Li T, Yang H, Xu J, Zhou L, Zhou X, Tang W, Song Y, Chen T, Bai T, Zhou J, Wang D, Wu G, Li D, Feng Z, Gao GF, Wang Y, He S, Shu Y (2016) Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings. J Infect 72(1):52–59. https://doi.org/10.1016/j.jinf.2015.06.009 CrossRefPubMed

38.

Chen T, Zhang R (2015) Symptoms seem to be mild in children infected with avian influenza A (H5N6) and other subtypes. J Infect 71(6):702–703. https://doi.org/10.1016/j.jinf.2015.09.004 CrossRefPubMed

39.

Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E (1999) Generation of influenza A viruses entirely from cloned cDNAs. PNAS 96(16):9345–9350. https://doi.org/10.1073/pnas.96.16.9345 CrossRefPubMed

40.

Bogs J, Veits J, Gohrbandt S, Hundt J, Stech O, Breithaupt A, Teifke JP, Mettenleiter TC, Stech J (2010) Highly pathogenic H5N1 influenza viruses carry virulence determinants beyond the polybasic hemagglutinin cleavage site. PLoS One 5(7):e11826. https://doi.org/10.1371/journal.pone.0011826 CrossRefPubMedPubMedCentral

41.

Li S, Liu C, Klimov A, Subbarao K, Perdue ML, Mo D, Ji Y, Woods L, Hietala S, Bryant M (1999) Recombinant influenza a virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 179(5):1132–1138. https://doi.org/10.1086/314713 CrossRefPubMed

42.

Suguitan AL Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3(9):e360. https://doi.org/10.1371/journal.pmed.0030360 CrossRefPubMedPubMedCentral

43.

Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368(9540):991–997. https://doi.org/10.1016/S0140-6736(06)69294-5 CrossRefPubMed

44.

Bresson J-L, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367(9523):1657–1664. https://doi.org/10.1016/S0140-6736(06)68656-X CrossRefPubMed

45.

Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358(24):2573–2584. https://doi.org/10.1056/NEJMoa073121 CrossRefPubMed

46.

Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nøstbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H (2011) Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 29(45):8049–8059. https://doi.org/10.1016/j.vaccine.2011.08.042 CrossRefPubMed

47.

Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A (2008) Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 4(8):e1000138. https://doi.org/10.1371/journal.ppat.1000138 CrossRefPubMedPubMedCentral

48.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J (2008) Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 380(2):412–420. https://doi.org/10.1016/j.virol.2008.08.002 CrossRefPubMed

49.

Couch RB, Decker WK, Utama B, Atmar RL, Niño D, Feng JQ, Halpert MM, Air GM (2012) Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One 7(12):e50830. https://doi.org/10.1371/journal.pone.0050830 CrossRefPubMedPubMedCentral

50.

De Groot AS, Ardito M, Terry F, Levitz L, Ross T, Moise L, Martin W (2013) Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum Vaccine Immunother 9(5):950–956. https://doi.org/10.4161/hv.24939 CrossRef

Title: Development and comparison of two H5N8 influenza A vaccine candidate strains
Authors: Mi-Seon Lee
Eun Young Jang
Junhyung Cho
Kisoon Kim
Chan Hee Lee
Hwajung Yi
Publication date: 01-01-2019
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 1/2019
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-018-4062-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Development and comparison of two H5N8 influenza A vaccine candidate strains

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Independent evolution of porcine reproductive and respiratory syndrome virus 2 with genetic heterogeneity in antigenic regions of structural proteins in Korea

The fecal virome of red-crowned cranes

Crude extracts of recombinant baculovirus expressing rabbit hemorrhagic disease virus 2 VLPs from both insect and rabbit cells protect rabbits from rabbit hemorrhagic disease caused by RHDV2

Development and application of a simple recombinase polymerase amplification assay for rapid point-of-care detection of feline herpesvirus type 1

Correction to: An estrogen antagonist, cyclofenil, has anti-dengue-virus activity

The complete genomic sequence of Rhinolophus gammaherpesvirus 1 isolated from a greater horseshoe bat

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page